Mitiglinide (also known as KAD-1229; S21403) is a Potassiun Channel blocker that is used as a blood glucose-lowering drug, it stimulates insulin secretion by closing the ATP-sensitive K+ channels in pancreatic beta-cells. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells. Mitiglinide may be potential useful for the treatment of type 2 diabetes.
理化性质和储存条件
| Molecular Weight (MW) | 315.41 |
|---|
| Formula | C19H24NO3 |
|---|
| CAS No. | 0145375-43-5 |
|---|
| Storage | -20℃ for 3 years in powder form |
|---|
| -80℃ for 2 years in solvent |
| Solubility (In vitro) | DMSO: <1 mg/mL |
|---|
| Water:<1 mg/mL |
| Ethanol: 2 mg/mL (2.99 mM) |
| SMILES Code | O=C(O)[C@@H](CC1=CC=CC=C1)CC(N2C[C@]3([H])CCCC[C@]3([H])C2)=O |
|---|
| Synonyms | KAD-1229; KAD 1229; KAD1229; S 21403; Mitiglinide; Glufast. |
|---|
实验参考方法
| In Vitro | In vitro activity: Mitiglinide (KAD-1229; S21403) is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist. IC50 value: Target: KATP channel Mitiglinide is a hypoglycemic agent that closes adenosine triphosphate (ATP)-sensitive potassium channels (KATP channel s) in the pancreatic β-islet cells. Mitiglinide stimulates insulin secretion by stimulating Ca2+ influx. |
|---|
| In Vivo |
|
|---|
| Animal model |
|
|---|
| Formulation & Dosage |
|
|---|
| References |
|
|---|
m.cnreagent.com